

At Brightstar Therapeutics, we are accelerating therapies that address unmet needs within ocular surface care.

OUR WORK

Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with ocular surface diseases. In 2023, Brightstar Therapeutics became the first company to offer a long-term solution for patients with impaired ocular healing through the BrightMEM™ corneal allograft, and we will continue to drive next-generation therapeutics for patients in need.

OUR COMMITMENTS



Provide Surgeon Support at Every Step

Whether it is medical affairs expertise, hands-on wet labs or reimbursement support, our team is ready to support surgeons as they adopt Brightstar Therapeutics into their practice.



Honor the Gift of Sight


Our BrightMEM allograft expands the amount of tissue that can be used for sight-restoring treatments. In addition, it is aseptically processed from tissue obtained from donated human corneas according to the current Good Tissue Practices (cGTP) regulations established by the US Food & Drug Administration (FDA).



Champion Patient Care We strongly believe that all patients deserve the care they need to thrive. That's why we invest in therapeutics that can effectively address some of the most untreated gaps within ophthalmology.

OUR FUTURE

Brightstar Therapeutics is committed to advancing innovative, life-changing therapies. Using our patented technology, we are developing a pipeline of cell therapy products to address ocular surface disease.



BRIGHTMEM PRELOADED™ CORNEAL ALLOGRAFT

BrightMEM Preloaded is the pre-stripped, pre-punched corneal allograft designed to make DMAK procedures faster and easier — with the same trusted BrightMEM tissue quality surgeons already rely on.

Composed of Descemet's Membrane, BrightMEM Preloaded acts as a robust, durable basement membrane that promotes corneal re-epithelialization for patients with impaired corneal healing.

CLINICAL HIGHLIGHTS (*Cornea Journal Article*)

- 84.8% complete epithelialization
- 28-day median healing time
- 91.9% graft retention
- 97.1% complete healing beyond 6 months
- 100% of patients with pre-op pain improved
- VA improved in 52.6% of cases
- Zero infectious complications

Hou JH, Tauber J, Shukla R. Descemet membrane anterior keratoplasty with BrightMEM corneal allograft: an innovative technique for treatment of nonhealing diseases of the ocular surface. *Cornea*. 2026;45(8):1068-1072.

WHO IS BRIGHTMEM FOR?

The ideal patient for DMAK with BrightMEM Corneal Allografts has non-healing corneal defects, including post-herpetic, post-surgical, atopic, and other conditions. Research confirms it is also appropriate for patients with 25-75% limbal stem cell deficiency, with or without an epithelial defect.

DMAK WITH BRIGHTMEM PRELOADED CORNEAL ALLOGRAFT OVERVIEW



Prepare the BrightMEM Preloaded Allograft

The BrightMEM Preloaded allograft is shipped in a glass cannula in corneal storage media vial. Remove the cannula from vial and attach a pre-filled syringe to the silicone connector.




Place the BrightMEM Preloaded Allograft

After performing an SK, remove the cap from the glass cannula over a sterile field. Hold a Paton spatula ahead of the ejection location to prevent the allograft traveling off the cornea as it exits the glass cannula. Be sure to eject the allograft SLOWLY.



Smooth Out the BrightMEM Preloaded Allograft

Use a non-toothed forceps or a 25G cannula tip to unscroll the tissue on the corneal surface. Confirm the graft is "right side up" by observation of the "S" stamp. Once the tissue is properly oriented, apply 2-3 drops of BSS to the surface and use the shaft of the 25G cannula to press down and sweep / squeegee over the graft to smooth it out, removing all wrinkles and fluid.



Secure the BrightMEM Preloaded Allograft

Apply fibrin glue, ensuring all edges are fully covered. Next, place a bandage contact lens over the glue.



Post-Operative Care

Keep the bandage contact lens in place and have the patient wear an eye shield at night for the first month.

Watch Procedure

For more detailed instructions, visit
www.brightstartx.com/surgeontraining



Register to Begin Requesting BrightMEM



859.800.7147

info@brightstartx.com

www.brightstartx.com

